selected publications
- Lessons Learned from National Heart, Lung, and Blood Institute Covid-19 Clinical Trials. NEJM evidence. 2024 Academic Article GET IT
-
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.
Journal of the American College of Cardiology.
2024
Academic Article
GET IT
Times cited: 1 - Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial. European heart journal. 2024 Academic Article GET IT
- Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. American heart journal. 2024 Academic Article GET IT
-
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.
Journal of the American College of Cardiology.
2024
Academic Article
GET IT
Times cited: 1 - Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. BMJ open. 2024 Academic Article GET IT
- Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA cardiology. 2024 Academic Article GET IT
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA cardiology. 2024 Academic Article GET IT
-
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
Journal of the American College of Cardiology.
2024
Academic Article
GET IT
Times cited: 1 -
Variation in Health Status With Invasive vs Conservative Management of Chronic Coronary Disease.
Journal of the American College of Cardiology.
2024
Academic Article
GET IT
Times cited: 1 - Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. Journal of clinical lipidology. 2024 Academic Article GET IT
- Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. The New England journal of medicine. 2024 Academic Article GET IT
- Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial. Journal of the American College of Cardiology. 2024 Academic Article GET IT
- Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES. European journal of preventive cardiology. 2024 Academic Article GET IT
- Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial. Journal of the American Heart Association. 2024 Academic Article GET IT
- Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association. 2024 Academic Article GET IT
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. Journal of the American Heart Association. 2023 Academic Article GET IT
- Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA cardiology. 2023 Academic Article GET IT
- Food Is Medicine: A Presidential Advisory From the American Heart Association. Circulation. 2023 Review GET IT
- Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes care. 2023 Academic Article GET IT
- Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests. Circulation. 2023 Academic Article GET IT
- Personalized digital behaviour interventions increase short-term physical activity: a randomized control crossover trial substudy of the MyHeart Counts Cardiovascular Health Study. European heart journal. Digital health. 2023 Academic Article GET IT
- Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. Journal of the American Heart Association. 2023 Academic Article GET IT
- Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. American heart journal. 2023 Academic Article GET IT
- Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. The Canadian journal of cardiology. 2023 Academic Article GET IT
- Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. European heart journal. 2023 Academic Article GET IT
- External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. Journal of thrombosis and thrombolysis. 2022 Academic Article GET IT
-
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
European heart journal. Cardiovascular pharmacotherapy.
2022
Academic Article
GET IT
Times cited: 6 -
Sociodemographic determinants of oral anticoagulant prescription in patients with atrial fibrillations: findings from the PINNACLE registry using machine learning.
Heart rhythm O2.
2022
Academic Article
GET IT
Times cited: 2 -
Survival After Invasive or Conservative Management of Stable Coronary Disease.
Circulation.
2022
Academic Article
GET IT
Times cited: 61 -
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.
Journal of the American College of Cardiology.
2022
Academic Article
GET IT
Times cited: 6 -
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab.
Journal of the American College of Cardiology.
2022
Letter
GET IT
Times cited: 1 -
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry.
International journal of cardiology.
2022
Academic Article
GET IT
Times cited: 1 - Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. Journal of clinical lipidology. 2022 Academic Article GET IT
- Response by Cavender et al to Letter Regarding Article, "Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX". Circulation. Cardiovascular interventions. 2022 Letter GET IT
-
Trials and Tribulations of Randomized Clinical Trials.
Circulation.
2022
Editorial Article
GET IT
Times cited: 1 -
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation.
2022
Academic Article
GET IT
Times cited: 50 -
A Retrospective Analysis of Medical Student Performance Evaluations, 2014-2020: Recommend with Reservations.
Journal of general internal medicine.
2022
Academic Article
GET IT
Times cited: 4 -
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial.
European heart journal. Acute cardiovascular care.
2022
Academic Article
GET IT
Times cited: 4 -
Iterative approaches to the use of electronic health records data for large pragmatic studies.
Contemporary clinical trials.
2022
Review
GET IT
Times cited: 1 -
Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial.
Circulation. Cardiovascular interventions.
2022
Academic Article
GET IT
Times cited: 4 -
Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI.
American heart journal.
2022
Academic Article
GET IT
Times cited: 1 - Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. The American journal of medicine. 2022 Academic Article GET IT
- Changing the Trajectory of Heart Failure and Kidney Disease: A Call for Action. Clinical journal of the American Society of Nephrology : CJASN. 2022 Academic Article GET IT
- Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation. Cardiovascular interventions. 2022 Academic Article GET IT
-
Diagnosis and Treatment of Acute Coronary Syndromes: A Review.
JAMA.
2022
Review
GET IT
Times cited: 104 - Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. Thrombosis research. 2022 Academic Article GET IT
-
Establishing a Data Science Unit in an Academic Medical Center: An Illustrative Model.
Academic medicine : journal of the Association of American Medical Colleges.
2022
Academic Article
GET IT
Times cited: 9 -
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Circulation. Cardiovascular interventions.
2021
Academic Article
GET IT
Times cited: 6 -
Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial.
Circulation. Cardiovascular interventions.
2021
Letter
GET IT
Times cited: 2 - Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention - Insights from the CHAMPION program. American heart journal plus : cardiology research and practice. 2021 Academic Article GET IT
-
The Pivotal Role of Women in Cardiology Sections in Medical Organizations: From Leadership Training to Personal Enrichment.
CJC open.
2021
Review
GET IT
Times cited: 1 -
Gender Disparities in Cardiology-Related COVID-19 Publications.
Cardiology and therapy.
2021
Academic Article
GET IT
Times cited: 2 -
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.
JAMA network open.
2021
Academic Article
GET IT
Times cited: 7 -
Increases in SARS-CoV-2 Test Positivity Rates Among Hispanic People in a Northern California Health System.
Public health reports (Washington, D.C. : 1974).
2021
Academic Article
GET IT
Times cited: 2 -
The Need to Expand the Framework of Environmental Determinants of Cardiovascular Health From Climate Change to Planetary Health: Trial by Wildfire.
Circulation.
2021
Academic Article
GET IT
Times cited: 4 -
Global Prevalence and Impact of Hostility, Discrimination, and Harassment in the Cardiology Workplace.
Journal of the American College of Cardiology.
2021
Academic Article
GET IT
Times cited: 28 -
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
The New England journal of medicine.
2021
Academic Article
GET IT
Times cited: 69 - Antithrombotic Therapy after Acute Coronary Syndromes. Reply. The New England journal of medicine. 2021 Letter GET IT
-
2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report.
Circulation.
2021
Conference Paper
GET IT
Times cited: 11 -
2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report.
Journal of the American College of Cardiology.
2021
Conference Paper
GET IT
Times cited: 12 - A Return to Normal Is Not Good Enough. Circulation. 2021 Letter GET IT
-
Taking a stand against air pollution - the impact on cardiovascular disease.
European heart journal.
2021
Academic Article
GET IT
Times cited: 15 -
Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement.
Circulation.
2021
Review
GET IT
Times cited: 1 - COVID-19 at 1 Year: American Heart Association Presidents Reflect on the Pandemic. Circulation. 2021 Academic Article GET IT
-
Risk Stratification Science Goes to a New Level.
JAMA cardiology.
2021
Comment
GET IT
Times cited: 5 -
Temporal Trends in the Proportion of Women Physician Speakers at Major Cardiovascular Conferences.
Circulation.
2021
Letter
GET IT
Times cited: 6 -
Management of Antithrombotic Therapy after Acute Coronary Syndromes.
The New England journal of medicine.
2021
Review
GET IT
Times cited: 74 -
Taking a Stand Against Air Pollution - The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology.
Global heart.
2021
Editorial Article
GET IT
Times cited: 10 -
Taking a Stand Against Air Pollution-The Impact on Cardiovascular Disease: A Joint Opinion From the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology.
Circulation.
2021
Review
GET IT
Times cited: 37 -
Taking a Stand Against Air Pollution-The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology.
Journal of the American College of Cardiology.
2021
Guideline
GET IT
Times cited: 34 -
Generating evidence for therapeutic effects: the need for well-conducted randomized trials.
The Journal of clinical investigation.
2021
Academic Article
GET IT
Times cited: 6 -
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
European heart journal.
2020
Academic Article
GET IT
Times cited: 138 -
The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review.
Journal of internal medicine.
2020
Review
GET IT
Times cited: 128 -
Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov.
JAMA internal medicine.
2020
Academic Article
GET IT
Times cited: 56 -
Machine learning and atherosclerotic cardiovascular disease risk prediction in a multi-ethnic population.
NPJ digital medicine.
2020
Academic Article
GET IT
Times cited: 59 -
A Path Forward.
Journal of the American Heart Association.
2020
Editorial Article
GET IT
Times cited: 2 -
Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week.
Journal of the American College of Cardiology.
2020
Review
GET IT
Times cited: 52 -
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.
Journal of the American College of Cardiology.
2020
Academic Article
GET IT
Times cited: 36 -
Association of Burnout, Professional Fulfillment, and Self-care Practices of Physician Leaders With Their Independently Rated Leadership Effectiveness.
JAMA network open.
2020
Academic Article
GET IT
Times cited: 59 - Protecting Our Front Line. Circulation. Cardiovascular interventions. 2020 Editorial Article GET IT
-
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Journal of the American College of Cardiology.
2020
Academic Article
GET IT
Times cited: 41 -
Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership.
Journal of the American College of Cardiology.
2020
Guideline
GET IT
Times cited: 37 -
Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership.
The Annals of thoracic surgery.
2020
Guideline
GET IT
Times cited: 15 -
Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership.
The Canadian journal of cardiology.
2020
Review
GET IT
Times cited: 15 -
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.
JAMA cardiology.
2020
Academic Article
GET IT
Times cited: 51 -
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
American heart journal.
2020
Academic Article
GET IT
Times cited: 3 -
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Heart rhythm.
2020
Guideline
GET IT
Times cited: 14 -
Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.
Journal of the American College of Cardiology.
2020
Guideline
GET IT
Times cited: 64 -
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
Circulation.
2020
Review
GET IT
Times cited: 110 -
Protecting Medical Trainees on the COVID-19 Frontlines Saves Us All.
Circulation.
2020
Letter
GET IT
Times cited: 27 -
Initial Invasive or Conservative Strategy for Stable Coronary Disease.
The New England journal of medicine.
2020
Academic Article
GET IT
Times cited: 1651 -
Video-based AI for beat-to-beat assessment of cardiac function.
Nature.
2020
Academic Article
GET IT
Times cited: 483 -
The Role of the American Heart Association in the Global COVID-19 Pandemic.
Circulation.
2020
Letter
GET IT
Times cited: 31 -
Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association.
Circulation.
2020
Academic Article
GET IT
Times cited: 119 -
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES.
Journal of the American College of Cardiology.
2020
Letter
GET IT
Times cited: 5 -
Advancing Healthcare Reform: The American Heart Association's 2020 Statement of Principles for Adequate, Accessible, and Affordable Health Care: A Presidential Advisory From the American Heart Association.
Circulation.
2020
Academic Article
GET IT
Times cited: 16 -
Deep learning interpretation of echocardiograms.
NPJ digital medicine.
2020
Academic Article
GET IT
Times cited: 277 -
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Journal of the American College of Cardiology.
2020
Academic Article
GET IT
Times cited: 234 -
Machine learning to predict venous thrombosis in acutely ill medical patients.
Research and practice in thrombosis and haemostasis.
2020
Academic Article
GET IT
Times cited: 22 -
Association Between Current and Future Annual Hospital Percutaneous Coronary Intervention Mortality Rates.
JAMA cardiology.
2019
Academic Article
GET IT
Times cited: 7 -
Consequences of Slow Progress Toward Pragmatism in Randomized Clinical Trials: It Is Time to Get Practical.
JAMA cardiology.
2019
Comment
GET IT
Times cited: 4 -
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke.
Stroke.
2019
Editorial Article
GET IT
Times cited: 225 -
The effect of digital physical activity interventions on daily step count: a randomised controlled crossover substudy of the MyHeart Counts Cardiovascular Health Study.
The Lancet. Digital health.
2019
Academic Article
GET IT
Times cited: 39 -
10 Recommendations to Enhance Recruitment, Retention, and Career Advancement of Women Cardiologists.
Journal of the American College of Cardiology.
2019
Review
GET IT
Times cited: 28 -
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.
Circulation.
2019
Review
GET IT
Times cited: 27 -
2019 ACC Health Policy Statement on Cardiologist Compensation and Opportunity Equity.
Journal of the American College of Cardiology.
2019
Academic Article
GET IT
Times cited: 9 -
Beyond duty hours: leveraging large-scale paging data to monitor resident workload.
NPJ digital medicine.
2019
Academic Article
GET IT
Times cited: 1 -
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
Journal of the American College of Cardiology.
2019
Academic Article
GET IT
Times cited: 35 -
Translating Science Into Policy: An Important Collaboration Among Researchers, Clinicians, and Advocacy at the American Heart Association.
Circulation.
2019
Letter
GET IT
Times cited: 1 -
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Circulation.
2019
Academic Article
GET IT
Times cited: 39 -
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
European heart journal.
2019
Academic Article
GET IT
Times cited: 46 -
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
The New England journal of medicine.
2019
Academic Article
GET IT
Times cited: 226 -
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Lancet (London, England).
2019
Academic Article
GET IT
Times cited: 143 -
A novel noninvasive method for remote heart failure monitoring: the EuleriAn video Magnification apPLications In heart Failure studY (AMPLIFY).
NPJ digital medicine.
2019
Academic Article
GET IT
Times cited: 15 -
Thrombophilia testing in the inpatient setting: impact of an educational intervention.
BMC medical informatics and decision making.
2019
Academic Article
GET IT
Times cited: 2 -
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
Circulation. Cardiovascular interventions.
2019
Academic Article
GET IT
Times cited: 11 -
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.
Circulation. Cardiovascular interventions.
2019
Academic Article
GET IT
Times cited: 7 -
Burnout and Career Satisfaction Among U.S. Cardiologists.
Journal of the American College of Cardiology.
2019
Academic Article
GET IT
Times cited: 53 -
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
The lancet. Diabetes & endocrinology.
2019
Academic Article
GET IT
Times cited: 189 -
The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.
Clinical cardiology.
2019
Academic Article
GET IT
Times cited: 3 -
Characteristics of Digital Health Studies Registered in ClinicalTrials.gov.
JAMA internal medicine.
2019
Academic Article
GET IT
Times cited: 35 -
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Circulation.
2019
Academic Article
GET IT
Times cited: 123 -
Prehospital Phase of Acute Stroke Care: Guideline and Policy Considerations as Science and Evidence Rapidly Evolve.
Stroke.
2019
Editorial Article
GET IT
Times cited: 9 -
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
American heart journal.
2019
Academic Article
GET IT
Times cited: 5 -
Stanford Cardiovascular Institute.
Circulation research.
2019
Article
GET IT
Times cited: 3 -
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?.
European heart journal.
2019
Academic Article
GET IT
Times cited: 24 -
Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women.
Circulation. Cardiovascular interventions.
2019
Academic Article
GET IT
Times cited: 6 -
Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017.
Diabetologia.
2019
Academic Article
GET IT
Times cited: 21 -
Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study.
Scientific data.
2019
Academic Article
GET IT
Times cited: 45 -
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Clinical cardiology.
2019
Academic Article
GET IT
Times cited: 24 -
It is time to learn from patients like mine.
NPJ digital medicine.
2019
Review
GET IT
Times cited: 27 -
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.
Journal of the American College of Cardiology.
2019
Academic Article
GET IT
Times cited: 139 - Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circulation. Cardiovascular interventions. 2019 Academic Article GET IT
-
What Is Needed Now to Improve Cardiovascular Clinical Registries in the Future.
JAMA cardiology.
2019
Comment
GET IT
Times cited: 2 -
Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.
Circulation.
2019
Letter
GET IT
Times cited: 5 -
Association Between Female Corresponding Authors and Female Co-Authors in Top Contemporary Cardiovascular Medicine Journals.
Circulation.
2019
Letter
GET IT
Times cited: 12 -
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Intensive care medicine.
2019
Academic Article
GET IT
Times cited: 15 -
One Size Does Not Fit All: Improving Recruitment and Retention of Women in Cardiovascular Device-Related Clinical Trials.
JACC. Cardiovascular interventions.
2019
Editorial Article
GET IT
Times cited: 2 -
Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training.
JACC. Cardiovascular interventions.
2019
Academic Article
GET IT
Times cited: 41 -
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.
Journal of the American Heart Association.
2018
Academic Article
GET IT
Times cited: 9 -
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
European heart journal.
2018
Academic Article
GET IT
Times cited: 53 -
Promise and Perils of Big Data and Artificial Intelligence in Clinical Medicine and Biomedical Research.
Circulation research.
2018
Review
GET IT
Times cited: 19 -
Sex Disparities in Authorship Order of Cardiology Scientific Publications.
Circulation. Cardiovascular quality and outcomes.
2018
Academic Article
GET IT
Times cited: 40 -
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.
International journal of cardiology.
2018
Academic Article
GET IT
Times cited: 6 -
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.
Thrombosis and haemostasis.
2018
Academic Article
GET IT
Times cited: 41 -
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Journal of the American College of Cardiology.
2018
Academic Article
GET IT
Times cited: 120 -
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine.
2018
Academic Article
GET IT
Times cited: 1872 -
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.
American journal of hematology.
2018
Academic Article
GET IT
Times cited: 42 -
County-Level Hispanic Ethnic Density and Cardiovascular Disease Mortality.
Journal of the American Heart Association.
2018
Academic Article
GET IT
Times cited: 17 -
Planning and Conducting the ISCHEMIA Trial.
Circulation.
2018
Academic Article
GET IT
Times cited: 18 -
Heart Centers for Women: Historical Perspective on Formation and Future Strategies to Reduce Cardiovascular Disease.
Circulation.
2018
Review
GET IT
Times cited: 35 -
Healthcare Service Utilization under a New Virtual Primary Care Delivery Model.
Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
2018
Academic Article
GET IT
Times cited: 17 -
Data Sharing-The Time Has (Not Yet?) Come.
JAMA cardiology.
2018
Editorial Article
GET IT
Times cited: 3 -
Men Versus Women.
Circulation. Cardiovascular interventions.
2018
Editorial Article
GET IT
Times cited: 1 -
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
Blood cells, molecules & diseases.
2018
Academic Article
GET IT
Times cited: 10 -
Evaluating Health Technology Through Pragmatic Trials: Novel Approaches to Generate High-Quality Evidence.
JAMA.
2018
Editorial Article
GET IT
Times cited: 16 -
Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation: Moving Hearts.
Journal of the American College of Cardiology.
2018
Review
GET IT
Times cited: 76 -
Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care.
Journal of the American College of Cardiology.
2018
Review
GET IT
Times cited: 124 -
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.
International journal of cardiology.
2018
Academic Article
GET IT
Times cited: 12 -
The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
2018
Review
GET IT
Times cited: 24 -
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.
2018
Academic Article
GET IT
Times cited: 25 -
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2018
Academic Article
GET IT
Times cited: 5 -
The TREAT Trial-Moving ST-Elevation Myocardial Infarction Care Forward, With More to Do.
JAMA cardiology.
2018
Editorial Article
GET IT
Times cited: 2 -
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design.
American heart journal.
2018
Review
GET IT
Times cited: 206 -
Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.
American heart journal.
2018
Academic Article
GET IT
Times cited: 5 -
Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA.
Circulation.
2018
Academic Article
GET IT
Times cited: 5 -
Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.
The American journal of medicine.
2018
Academic Article
GET IT
Times cited: 25 -
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Circulation. Cardiovascular interventions.
2018
Academic Article
GET IT
Times cited: 14 -
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
2018
Academic Article
GET IT
Times cited: 17 -
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory.
Journal of the American College of Cardiology.
2018
Review
GET IT
Times cited: 35 -
Canakinumab for Atherosclerotic Disease.
The New England journal of medicine.
2018
Letter
GET IT
Times cited: 1 - Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH open : companion journal to thrombosis and haemostasis. 2018 Academic Article GET IT
-
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
Circulation.
2018
Letter
GET IT
Times cited: 28 -
What This Computer Needs Is a Physician: Humanism and Artificial Intelligence.
JAMA.
2018
Academic Article
GET IT
Times cited: 224 -
Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
Journal of thrombosis and thrombolysis.
2018
Academic Article
GET IT
Times cited: 15 -
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
American heart journal.
2017
Academic Article
GET IT
Times cited: 15 -
Nativity Status and Cardiovascular Disease Mortality Among Hispanic Adults.
Journal of the American Heart Association.
2017
Academic Article
GET IT
Times cited: 39 -
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.
Thrombosis and haemostasis.
2017
Academic Article
GET IT
Times cited: 22 -
Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling.
JAMA cardiology.
2017
Editorial Article
GET IT
Times cited: 10 -
Resuscitating Cardiovascular Drug Development.
JAMA cardiology.
2017
Academic Article
GET IT
Times cited: 2 - Author Relationships With Industry: Policies and Procedures for Authors and Editors of JAMA Cardiology. JAMA cardiology. 2017 Editorial Article GET IT
-
N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy.
Journal of thrombosis and thrombolysis.
2017
Academic Article
GET IT
Times cited: 9 -
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
American heart journal.
2017
Academic Article
GET IT
Times cited: 5 -
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
American heart journal.
2017
Academic Article
GET IT
Times cited: 8 -
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
International journal of cardiology.
2017
Academic Article
GET IT
Times cited: 5 -
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Journal of thrombosis and haemostasis : JTH.
2017
Academic Article
GET IT
Times cited: 21 -
Targeting Inflammation in Coronary Artery Disease.
The New England journal of medicine.
2017
Editorial Article
GET IT
Times cited: 91 -
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Pharmaceutical statistics.
2017
Academic Article
GET IT
Times cited: 8 -
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX.
Circulation. Cardiovascular interventions.
2017
Academic Article
GET IT
Times cited: 7 - Unreliable Observations from a Confounded Analysis of a Skewed Database. The American journal of medicine. 2017 Letter GET IT
-
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
The American journal of cardiology.
2017
Academic Article
GET IT
Times cited: 10 -
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.
International journal of cardiology.
2017
Academic Article
GET IT
Times cited: 19 -
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Journal of the American Heart Association.
2017
Academic Article
GET IT
Times cited: 35 -
One-Year Follow-up of the European Ambulance Acute Coronary Syndrome Angiography Trial.
JAMA cardiology.
2017
Comment
GET IT
Times cited: 1 - The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH open : companion journal to thrombosis and haemostasis. 2017 Academic Article GET IT
- Integrating Research With Clinical Practice: Keeping It Simple. JAMA cardiology. 2017 Comment GET IT
-
Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect.
Journal of the American College of Cardiology.
2017
Editorial Article
GET IT
Times cited: 3 -
Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery.
Journal of the American College of Cardiology.
2017
Review
GET IT
Times cited: 46 -
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites.
The American journal of medicine.
2017
Academic Article
GET IT
Times cited: 7 -
New Delivery Model for Rising-Risk Patients: The Forgotten Lot?.
Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
2017
Academic Article
GET IT
Times cited: 3 -
When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials.
American heart journal.
2017
Editorial Article
GET IT
Times cited: 11 -
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials.
Journal of the American College of Cardiology.
2017
Review
GET IT
Times cited: 43 -
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
The New England journal of medicine.
2017
Academic Article
GET IT
Times cited: 197 -
The Academic Medical System: Reinvention to Survive the Revolution in Health Care.
Journal of the American College of Cardiology.
2017
Review
GET IT
Times cited: 22 -
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
European heart journal.
2017
Academic Article
GET IT
Times cited: 266 -
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
American heart journal.
2017
Academic Article
GET IT
Times cited: 2 -
Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups.
JAMA cardiology.
2017
Academic Article
GET IT
Times cited: 48 -
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
American heart journal.
2017
Academic Article
GET IT
Times cited: 22 -
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
JAMA cardiology.
2017
Academic Article
GET IT
Times cited: 35 -
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.
Journal of the American College of Cardiology.
2017
Academic Article
GET IT
Times cited: 39 -
The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction.
PloS one.
2017
Academic Article
GET IT
Times cited: 1 -
Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.
International journal of cardiology.
2017
Academic Article
GET IT
Times cited: 4 -
Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study.
JAMA cardiology.
2017
Academic Article
GET IT
Times cited: 162 -
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Circulation. Cardiovascular interventions.
2017
Academic Article
GET IT
Times cited: 5 -
Statins-Almost 30 Years of Use in the United States and Still Not Quite There.
JAMA cardiology.
2017
Comment
GET IT
Times cited: 14 -
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
American heart journal.
2016
Academic Article
GET IT
Times cited: 47 -
Betrixaban in Acutely Ill Medical Patients.
The New England journal of medicine.
2016
Letter
GET IT
Times cited: 1 -
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.
Clinical chemistry.
2016
Academic Article
GET IT
Times cited: 25 -
Twitter and Cardiovascular Disease: Useful Chirps or Noisy Chatter?.
JAMA cardiology.
2016
Academic Article
GET IT
Times cited: 4 -
Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
JAMA.
2016
Academic Article
GET IT
Times cited: 17 -
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Circulation.
2016
Academic Article
GET IT
Times cited: 141 -
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Circulation.
2016
Academic Article
GET IT
Times cited: 57 -
The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation?.
Academic medicine : journal of the Association of American Medical Colleges.
2016
Academic Article
GET IT
Times cited: 25 -
The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease.
Journal of the American College of Cardiology.
2016
Review
GET IT
Times cited: 63 -
The Outlook of Digital Health for Cardiovascular Medicine: Challenges but Also Extraordinary Opportunities.
JAMA cardiology.
2016
Academic Article
GET IT
Times cited: 32 -
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
JACC. Cardiovascular interventions.
2016
Academic Article
GET IT
Times cited: 31 -
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
European heart journal. Acute cardiovascular care.
2016
Academic Article
GET IT
Times cited: 1 -
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial.
American heart journal.
2016
Academic Article
GET IT
Times cited: 23 -
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings.
Journal of the American College of Cardiology.
2016
Letter
GET IT
Times cited: 6 -
Sharing Data from Cardiovascular Clinical Trials--A Proposal.
The New England journal of medicine.
2016
Academic Article
GET IT
Times cited: 41 -
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.
European heart journal. Acute cardiovascular care.
2016
Academic Article
GET IT
Times cited: 6 -
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Circulation.
2016
Academic Article
GET IT
Times cited: 36 -
Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression.
International journal of cardiology.
2016
Review
GET IT
Times cited: 7 -
Defining a Mobile Health Roadmap for Cardiovascular Health and Disease.
Journal of the American Heart Association.
2016
Review
GET IT
Times cited: 40 -
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.
American heart journal.
2016
Academic Article
GET IT
Times cited: 24 -
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Journal of the American Heart Association.
2016
Academic Article
GET IT
Times cited: 55 -
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
American heart journal.
2016
Academic Article
GET IT
Times cited: 5 -
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Circulation. Cardiovascular interventions.
2016
Academic Article
GET IT
Times cited: 11 -
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
The New England journal of medicine.
2016
Academic Article
GET IT
Times cited: 353 -
Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial".
Circulation.
2016
Letter
GET IT
Times cited: 1 -
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.
Journal of the American College of Cardiology.
2016
Academic Article
GET IT
Times cited: 58 -
Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study.
Cell transplantation.
2016
Academic Article
GET IT
Times cited: 54 -
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy.
Circulation. Cardiovascular interventions.
2016
Academic Article
GET IT
Times cited: 13 -
Wearable Fitness Trackers and Heart Disease.
JAMA cardiology.
2016
Academic Article
GET IT
Times cited: 12 -
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
American heart journal.
2016
Academic Article
GET IT
Times cited: 12 -
A resident-created hospitalist curriculum for internal medicine housestaff.
Journal of hospital medicine.
2016
Academic Article
GET IT
Times cited: 5 -
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
American heart journal.
2016
Academic Article
GET IT
Times cited: 25 -
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.
JAMA cardiology.
2016
Academic Article
GET IT
Times cited: 18 -
Coronary Artery Bypass Surgery Is Not Underutilized!.
Circulation.
2016
Review
GET IT
Times cited: 4 -
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials.
Circulation.
2016
Review
GET IT
Times cited: 15 -
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.
Journal of the American College of Cardiology.
2016
Letter
GET IT
Times cited: 22 -
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Heart (British Cardiac Society).
2016
Academic Article
GET IT
Times cited: 52 -
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
Circulation.
2016
Academic Article
GET IT
Times cited: 27 -
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2015
Academic Article
GET IT
Times cited: 7 -
Tooth loss is independently associated with poor outcomes in stable coronary heart disease.
European journal of preventive cardiology.
2015
Academic Article
GET IT
Times cited: 28 -
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.
Journal of the American Heart Association.
2015
Academic Article
GET IT
Times cited: 9 -
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial.
Circulation.
2015
Academic Article
GET IT
Times cited: 80 -
Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.
Journal of the American College of Cardiology.
2015
Review
GET IT
Times cited: 92 -
Appropriate Use Criteria for Coronary Revascularization and the Learning Health System: A Good Start.
JAMA.
2015
Editorial Article
GET IT
Times cited: 4 -
Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions.
International journal of cardiology.
2015
Academic Article
GET IT
Times cited: 6 -
The Role of Peer Support in Attaining Ideal Cardiovascular Health: Peer Pressure and Prevention.
Journal of the American College of Cardiology.
2015
Editorial Article
GET IT
Times cited: 1 -
Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015.
Journal of the American Heart Association.
2015
Conference Paper
GET IT
Times cited: 39 -
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
2015
Academic Article
GET IT
Times cited: 52 -
Team-Based Care and Quality: A Move Toward Evidence-Based Policy.
Journal of the American College of Cardiology.
2015
Editorial Article
GET IT
Times cited: 7 -
Clinician Innovator: A Novel Career Path in Academic Medicine A Presidentially Commissioned Article From the American Heart Association.
Journal of the American Heart Association.
2015
Academic Article
GET IT
Times cited: 15 -
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
Journal of thrombosis and thrombolysis.
2015
Academic Article
GET IT
Times cited: 25 -
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
European heart journal.
2015
Academic Article
GET IT
Times cited: 24 -
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction.
American heart journal.
2015
Academic Article
GET IT
Times cited: 13 -
Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need.
Journal of cardiovascular pharmacology and therapeutics.
2015
Review
GET IT
Times cited: 8 -
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years.
Circulation. Cardiovascular quality and outcomes.
2015
Academic Article
GET IT
Times cited: 31 -
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome.
Heart (British Cardiac Society).
2015
Academic Article
GET IT
Times cited: 13 -
Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.
Journal of the American Heart Association.
2015
Review
GET IT
Times cited: 22 -
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.
Circulation. Cardiovascular interventions.
2015
Academic Article
GET IT
Times cited: 17 -
Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy.
American heart journal.
2015
Academic Article
GET IT
Times cited: 30 -
Selecting revascularization strategies in patients with coronary disease.
The New England journal of medicine.
2015
Editorial Article
GET IT
Times cited: 8 -
COCATS 4 Task Force 15: Training in Cardiovascular Research and Scholarly Activity.
Journal of the American College of Cardiology.
2015
Review
GET IT
Times cited: 20 -
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations.
American heart journal.
2015
Review
GET IT
Times cited: 16 -
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
The American journal of cardiology.
2015
Academic Article
GET IT
Times cited: 15 -
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
JACC. Cardiovascular interventions.
2015
Academic Article
GET IT
Times cited: 32 -
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Journal of the American College of Cardiology.
2015
Academic Article
GET IT
Times cited: 24 -
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.
American heart journal.
2015
Academic Article
GET IT
Times cited: 8 -
D-Dimer elevation and adverse outcomes.
Journal of thrombosis and thrombolysis.
2015
Review
GET IT
Times cited: 79 -
Organizational Change, Leadership, and the Transformation of Continuing Professional Development: Lessons Learned From the American College of Cardiology.
The Journal of continuing education in the health professions.
2015
Academic Article
GET IT
Times cited: 4 -
Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction.
JAMA.
2014
Review
GET IT
Times cited: 238 -
A message from modern-day healthcare to physical activity and fitness: welcome home!.
Progress in cardiovascular diseases.
2014
Editorial Article
GET IT
Times cited: 41 -
The future of clinical research and the ACC: empowerment through registries, data, and our members.
Journal of the American College of Cardiology.
2014
Review
GET IT
Times cited: 6 -
More than 10 million steps in the right direction: results from the first American Heart Association scientific sessions walking challenge.
Progress in cardiovascular diseases.
2014
Academic Article
GET IT
Times cited: 8 -
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.
American heart journal.
2014
Letter
GET IT
Times cited: 9 -
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
American heart journal.
2014
Academic Article
GET IT
Times cited: 20 - Advances in understanding percutaneous coronary intervention pharmacology: ischemia, bleeding, the ISAR research group, and a commitment to progress. Coronary artery disease. 2014 Comment GET IT
-
Predictors of contemporary coronary artery bypass grafting outcomes.
The Journal of thoracic and cardiovascular surgery.
2014
Academic Article
GET IT
Times cited: 23 -
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
American heart journal.
2014
Academic Article
GET IT
Times cited: 358 - Calculating risks and benefits to help guide revascularization decisions: turning all available data into useful information. Journal of the American College of Cardiology. 2014 Editorial Article GET IT
-
A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial.
JACC. Cardiovascular interventions.
2014
Academic Article
GET IT
Times cited: 201 -
Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial.
JAMA surgery.
2014
Academic Article
GET IT
Times cited: 77 -
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
American heart journal.
2014
Academic Article
GET IT
Times cited: 44 -
A 'green button' for using aggregate patient data at the point of care.
Health affairs (Project Hope).
2014
Academic Article
GET IT
Times cited: 111 -
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.
International journal of cardiology.
2014
Letter
GET IT
Times cited: 5 -
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
The American journal of cardiology.
2014
Academic Article
GET IT
Times cited: 16 -
Antiplatelet and anticoagulation therapy for acute coronary syndromes.
Circulation research.
2014
Review
GET IT
Times cited: 72 -
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Circulation.
2014
Letter
GET IT
Times cited: 4 -
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
Thrombosis and haemostasis.
2014
Article
GET IT
Times cited: 4 -
Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes.
American heart journal.
2014
Academic Article
GET IT
Times cited: 9 -
From abstract to peer-reviewed publication: country matters.
International journal of cardiology.
2014
Letter
GET IT
Times cited: 1 -
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
European heart journal.
2014
Academic Article
GET IT
Times cited: 181 -
Darapladib for preventing ischemic events in stable coronary heart disease.
The New England journal of medicine.
2014
Academic Article
GET IT
Times cited: 436 -
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
European heart journal. Acute cardiovascular care.
2014
Academic Article
GET IT
Times cited: 12 -
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.
Clinical cardiology.
2014
Academic Article
GET IT
Times cited: 9 -
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Journal of the American College of Cardiology.
2014
Academic Article
GET IT
Times cited: 44 -
Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
The American journal of cardiology.
2014
Academic Article
GET IT
Times cited: 8 -
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Thrombosis and haemostasis.
2014
Academic Article
GET IT
Times cited: 31 -
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
The American journal of cardiology.
2013
Academic Article
GET IT
Times cited: 17 -
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
American heart journal.
2013
Academic Article
GET IT
Times cited: 75 -
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Journal of the American College of Cardiology.
2013
Academic Article
GET IT
Times cited: 42 -
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.
International journal of cardiology.
2013
Letter
GET IT
Times cited: 10 -
EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy.
Journal of thrombosis and thrombolysis.
2013
Academic Article
GET IT
Times cited: 18 -
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.
Journal of thrombosis and thrombolysis.
2013
Academic Article
GET IT
Times cited: 13 -
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
Journal of the American College of Cardiology.
2013
Academic Article
GET IT
Times cited: 72 -
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
Circulation.
2013
Academic Article
GET IT
Times cited: 106 -
Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis.
Journal of cardiothoracic and vascular anesthesia.
2013
Review
GET IT
Times cited: 93 -
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial.
American heart journal.
2013
Academic Article
GET IT
Times cited: 22 -
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Lancet (London, England).
2013
Review
GET IT
Times cited: 266 -
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
European heart journal. Acute cardiovascular care.
2013
Academic Article
GET IT
Times cited: 9 -
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2013
Academic Article
GET IT
Times cited: 93 -
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Circulation.
2013
Academic Article
GET IT
Times cited: 116 -
Platelet inhibition with cangrelor during PCI.
The New England journal of medicine.
2013
Letter
GET IT
Times cited: 4 -
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
American heart journal.
2013
Academic Article
GET IT
Times cited: 3 -
Response to letters regarding article, “Conversion of cardiovascular conference abstracts to publications”.
Circulation.
2013
Letter
GET IT
Times cited: 2 -
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
JACC. Cardiovascular interventions.
2013
Academic Article
GET IT
Times cited: 41 - Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Letter GET IT
-
Assessing research results in the medical literature: trust but verify.
JAMA internal medicine.
2013
Academic Article
GET IT
Times cited: 8 -
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
The American journal of medicine.
2013
Academic Article
GET IT
Times cited: 7 -
A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Transfusion.
2013
Academic Article
GET IT
Times cited: 119 -
Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes.
JACC. Heart failure.
2013
Academic Article
GET IT
Times cited: 45 -
2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards).
Critical pathways in cardiology.
2013
Academic Article
GET IT
Times cited: 16 -
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”.
Circulation.
2013
Letter
GET IT
Times cited: 1 -
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.
Journal of the American College of Cardiology.
2013
Review
GET IT
Times cited: 33 -
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients.
European heart journal. Acute cardiovascular care.
2013
Academic Article
GET IT
Times cited: 57 -
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.
American heart journal.
2013
Academic Article
GET IT
Times cited: 80 -
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Stroke.
2013
Academic Article
GET IT
Times cited: 7 -
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes.
Journal of the American College of Cardiology.
2013
Letter
GET IT
Times cited: 1 -
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting.
Journal of thrombosis and haemostasis : JTH.
2013
Letter
GET IT
Times cited: 8 -
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
European heart journal.
2013
Academic Article
GET IT
Times cited: 37 - ACP Journal Club. PCI using drug-eluting stents had higher mortality than CABG in diabetes and multivessel CAD. Annals of internal medicine. 2013 Comment GET IT
-
Rescuing clinical trials in the United States and beyond: a call for action.
American heart journal.
2013
Review
GET IT
Times cited: 42 -
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
The New England journal of medicine.
2013
Academic Article
GET IT
Times cited: 667 -
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial.
Heart (British Cardiac Society).
2013
Academic Article
GET IT
Times cited: 29 -
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy.
American heart journal.
2013
Academic Article
GET IT
Times cited: 20 -
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome.
American heart journal.
2013
Academic Article
GET IT
Times cited: 76 -
2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards).
Circulation.
2013
Academic Article
GET IT
Times cited: 119 -
2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards).
Journal of the American College of Cardiology.
2013
Academic Article
GET IT
Times cited: 97 - ACP Journal Club. Intraaortic balloon counterpulsation did not reduce mortality in acute MI with cardiogenic shock. Annals of internal medicine. 2012 Comment GET IT
-
Are central institutional review boards the solution? The National Heart, Lung, and Blood Institute Working Group's report on optimizing the IRB process.
Academic medicine : journal of the Association of American Medical Colleges.
2012
Academic Article
GET IT
Times cited: 21 -
Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being.
JAMA.
2012
Academic Article
GET IT
Times cited: 39 -
Conversion of cardiovascular conference abstracts to publications.
Circulation.
2012
Academic Article
GET IT
Times cited: 46 -
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI.
American heart journal.
2012
Academic Article
GET IT
Times cited: 14 -
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.
The Journal of thoracic and cardiovascular surgery.
2012
Guideline
GET IT
Times cited: 110 -
Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
JACC. Cardiovascular interventions.
2012
Academic Article
GET IT
Times cited: 18 -
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
American heart journal.
2012
Academic Article
GET IT
Times cited: 39 -
Lecture halls without lectures.
The New England journal of medicine.
2012
Letter
GET IT
Times cited: 4 -
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
American heart journal.
2012
Academic Article
GET IT
Times cited: 50 -
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
International journal of cardiology.
2012
Academic Article
GET IT
Times cited: 14 -
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial.
JAMA.
2012
Academic Article
GET IT
Times cited: 37 - Usefulness of medical conferences. JAMA. 2012 Letter GET IT
- Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. Journal of thrombosis and thrombolysis. 2012 Academic Article GET IT
-
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
Journal of thrombosis and thrombolysis.
2012
Academic Article
GET IT
Times cited: 124 -
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Circulation. Cardiovascular interventions.
2012
Academic Article
GET IT
Times cited: 83 -
Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes.
Circulation.
2012
Academic Article
GET IT
Times cited: 66 -
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
Circulation. Cardiovascular interventions.
2012
Academic Article
GET IT
Times cited: 30 -
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
American heart journal.
2012
Academic Article
GET IT
Times cited: 71 -
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2012
Guideline
GET IT
Times cited: 22 -
Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial.
Circulation. Cardiovascular quality and outcomes.
2012
Academic Article
GET IT
Times cited: 40 -
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.
International journal of cardiology.
2012
Review
GET IT
Times cited: 10 -
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
American heart journal.
2012
Academic Article
GET IT
Times cited: 96 -
Road mapping ATLAS ACS 2: are we there yet?.
European heart journal.
2012
Editorial Article
GET IT
Times cited: 2 -
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Circulation.
2012
Academic Article
GET IT
Times cited: 166 -
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery.
Circulation.
2012
Academic Article
GET IT
Times cited: 135 -
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Circulation.
2011
Academic Article
GET IT
Times cited: 38 -
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
European heart journal.
2011
Academic Article
GET IT
Times cited: 319 -
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
The New England journal of medicine.
2011
Academic Article
GET IT
Times cited: 672 -
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.
American heart journal.
2011
Academic Article
GET IT
Times cited: 7 -
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
The American journal of cardiology.
2011
Academic Article
GET IT
Times cited: 66 -
Biomedical innovation: a risky business at risk.
Science translational medicine.
2011
Academic Article
GET IT
Times cited: 3 -
American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy?.
Journal of the American College of Cardiology.
2011
Editorial Article
GET IT
Times cited: 33 -
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
Journal of thrombosis and thrombolysis.
2011
Academic Article
GET IT
Times cited: 2 -
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
European heart journal.
2011
Academic Article
GET IT
Times cited: 176 -
Apixaban with antiplatelet therapy after acute coronary syndrome.
The New England journal of medicine.
2011
Academic Article
GET IT
Times cited: 920 -
Intramyocardial, autologous CD34+ cell therapy for refractory angina.
Circulation research.
2011
Academic Article
GET IT
Times cited: 424 -
Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.
Journal of thrombosis and thrombolysis.
2011
Academic Article
GET IT
Times cited: 25 - Dueling registries?: an alternative perspective and the case for competitive collaboration. Circulation. Cardiovascular quality and outcomes. 2011 Comment GET IT
-
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Circulation. Cardiovascular quality and outcomes.
2011
Review
GET IT
Times cited: 33 -
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.
Circulation.
2011
Academic Article
GET IT
Times cited: 80 -
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Circulation.
2011
Academic Article
GET IT
Times cited: 376 -
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
BMJ (Clinical research ed.).
2011
Academic Article
GET IT
Times cited: 261 -
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
JAMA.
2011
Academic Article
GET IT
Times cited: 198 -
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.
Journal of the American College of Cardiology.
2011
Academic Article
GET IT
Times cited: 118 -
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
Circulation.
2011
Academic Article
GET IT
Times cited: 287 -
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).
Thrombosis and haemostasis.
2011
Editorial Article
GET IT
Times cited: 31 -
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
Circulation.
2011
Academic Article
GET IT
Times cited: 34 -
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.
Journal of the American Society of Hypertension : JASH.
2011
Conference Paper
GET IT
Times cited: 129 -
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Journal of the American College of Cardiology.
2010
Academic Article
GET IT
Times cited: 449 -
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.
American heart journal.
2010
Academic Article
GET IT
Times cited: 17 -
ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance.
Journal of the American College of Cardiology.
2010
Guideline
GET IT
Times cited: 818 -
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Circulation.
2010
Academic Article
GET IT
Times cited: 455 -
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.
American heart journal.
2010
Academic Article
GET IT
Times cited: 19 -
Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting.
The American journal of cardiology.
2010
Academic Article
GET IT
Times cited: 47 -
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
American heart journal.
2010
Academic Article
GET IT
Times cited: 115 - President's page: the ACC reconfirms commitment to transparent relationships with industry. Journal of the American College of Cardiology. 2010 Article GET IT
-
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Thrombosis and haemostasis.
2010
Academic Article
GET IT
Times cited: 55 -
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Circulation.
2010
Academic Article
GET IT
Times cited: 355 -
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Circulation.
2010
Academic Article
GET IT
Times cited: 82 -
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
American heart journal.
2010
Academic Article
GET IT
Times cited: 77 -
There is a role for industry-sponsored education in cardiology.
Circulation.
2010
Academic Article
GET IT
Times cited: 17 -
Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2010
Academic Article
GET IT
Times cited: 18 -
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Clinical cardiology.
2010
Academic Article
GET IT
Times cited: 52 -
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
American heart journal.
2010
Editorial Article
GET IT
Times cited: 87 -
Metabolic syndrome is not associated with increased mortality or cardiovascular risk in nondiabetic patients with a new diagnosis of coronary artery disease.
Circulation. Cardiovascular quality and outcomes.
2010
Academic Article
GET IT
Times cited: 8 -
Towards a new order in cardiovascular medicine: re-engineering through global collaboration.
European heart journal.
2010
Academic Article
GET IT
Times cited: 8 -
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
The American journal of medicine.
2010
Academic Article
GET IT
Times cited: 38 -
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Lancet (London, England).
2010
Academic Article
GET IT
Times cited: 620 -
Intravenous platelet blockade with cangrelor during PCI.
The New England journal of medicine.
2009
Academic Article
GET IT
Times cited: 519 -
Platelet inhibition with cangrelor in patients undergoing PCI.
The New England journal of medicine.
2009
Academic Article
GET IT
Times cited: 501 -
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
American heart journal.
2009
Academic Article
GET IT
Times cited: 107 -
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.
American heart journal.
2009
Conference Paper
GET IT
Times cited: 40 -
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
JACC. Cardiovascular interventions.
2009
Academic Article
GET IT
Times cited: 41 -
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial.
American heart journal.
2009
Academic Article
GET IT
Times cited: 36 -
Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs.
Journal of thrombosis and thrombolysis.
2009
Review
GET IT
Times cited: 26 -
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
The American journal of cardiology.
2009
Academic Article
GET IT
Times cited: 2 -
Antithrombotics in acute coronary syndromes.
Journal of the American College of Cardiology.
2009
Review
GET IT
Times cited: 49 -
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
The New England journal of medicine.
2009
Academic Article
GET IT
Times cited: 5806 -
Sex differences in mortality following acute coronary syndromes.
JAMA.
2009
Academic Article
GET IT
Times cited: 451 -
Premature release of data from clinical trials of ezetimibe.
The New England journal of medicine.
2009
Academic Article
GET IT
Times cited: 27 -
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery.
The New England journal of medicine.
2009
Academic Article
GET IT
Times cited: 298 -
A new generation of antiplatelet agents.
Current opinion in cardiology.
2009
Review
GET IT
Times cited: 9 -
Careers for clinician investigators.
Circulation.
2009
Academic Article
GET IT
Times cited: 9 -
Defining the length of stay following percutaneous coronary intervention: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Endorsed by the American College of Cardiology Foundation.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2009
Guideline
GET IT
Times cited: 86 -
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Circulation.
2009
Academic Article
GET IT
Times cited: 433 -
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
International journal of cardiology.
2009
Academic Article
GET IT
Times cited: 22 -
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Circulation.
2009
Academic Article
GET IT
Times cited: 79 -
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
International journal of clinical practice.
2009
Academic Article
GET IT
Times cited: 14 -
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
American heart journal.
2009
Academic Article
GET IT
Times cited: 353 -
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography.
American heart journal.
2009
Academic Article
GET IT
Times cited: 114 -
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.
European heart journal.
2009
Academic Article
GET IT
Times cited: 116 -
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.
Circulation.
2009
Conference Paper
GET IT
Times cited: 913 -
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
The New England journal of medicine.
2009
Academic Article
GET IT
Times cited: 433 -
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Lancet (London, England).
2009
Academic Article
GET IT
Times cited: 304 -
Ethical and scientific implications of the globalization of clinical research.
The New England journal of medicine.
2009
Academic Article
GET IT
Times cited: 566 -
Optimizing trial design: sequential, adaptive, and enrichment strategies.
Circulation.
2009
Review
GET IT
Times cited: 86 -
Aldehyde dehydrogenase activity allows reliable EPC enumeration in stored peripheral blood samples.
Journal of thrombosis and thrombolysis.
2009
Academic Article
GET IT
Times cited: 9 -
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
The American journal of cardiology.
2008
Academic Article
GET IT
Times cited: 9 -
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
American heart journal.
2008
Academic Article
GET IT
Times cited: 274 -
Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery.
The Journal of thoracic and cardiovascular surgery.
2008
Academic Article
GET IT
Times cited: 19 -
Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.
The American journal of cardiology.
2008
Academic Article
GET IT
Times cited: 5 -
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
Antimicrobial agents and chemotherapy.
2008
Academic Article
GET IT
Times cited: 11 -
Long-term clinical outcomes following coronary stenting.
Archives of internal medicine.
2008
Academic Article
GET IT
Times cited: 14 -
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
The American journal of cardiology.
2008
Academic Article
GET IT
Times cited: 52 -
Late adverse events after drug-eluting stent implantation.
Current cardiology reports.
2008
Academic Article
GET IT
Times cited: 2 -
Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration.
Circulation.
2008
Academic Article
GET IT
Times cited: 7 -
Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008
Guideline
GET IT
Times cited: 105 -
Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008
Guideline
GET IT
Times cited: 292 -
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008
Guideline
GET IT
Times cited: 144 -
Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008
Guideline
GET IT
Times cited: 319 -
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008
Guideline
GET IT
Times cited: 219 -
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Circulation.
2008
Academic Article
GET IT
Times cited: 112 -
Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace?.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
2008
Comment
GET IT
Times cited: 13 -
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.
American heart journal.
2008
Academic Article
GET IT
Times cited: 7 -
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
JAMA.
2008
Academic Article
GET IT
Times cited: 49 -
Outcomes of second revascularization procedures after stent implantation.
Journal of medical systems.
2008
Academic Article
GET IT
Times cited: 8 -
Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
The Journal of cardiovascular surgery.
2008
Academic Article
GET IT
Times cited: 4 -
Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.
Journal of the American College of Cardiology.
2008
Academic Article
GET IT
Times cited: 117 -
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.
Heart (British Cardiac Society).
2008
Review
GET IT
Times cited: 162 -
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes.
American heart journal.
2008
Academic Article
GET IT
Times cited: 96 -
Noninvasive, medical management for non-ST-elevation acute coronary syndromes.
American heart journal.
2008
Review
GET IT
Times cited: 21 -
Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease.
Clinical cardiology.
2008
Academic Article
GET IT
Times cited: 18 -
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.
American heart journal.
2008
Academic Article
GET IT
Times cited: 7 -
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
Journal of thrombosis and haemostasis : JTH.
2008
Academic Article
GET IT
Times cited: 94 -
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Circulation.
2008
Academic Article
GET IT
Times cited: 147 -
Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV.
The Annals of thoracic surgery.
2008
Academic Article
GET IT
Times cited: 101 -
Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters.
The Annals of thoracic surgery.
2008
Academic Article
GET IT
Times cited: 8 -
Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?.
Journal of the American College of Cardiology.
2008
Editorial Article
GET IT
Times cited: 8 -
Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites.
The American journal of cardiology.
2007
Review
GET IT
Times cited: 23 -
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes.
American heart journal.
2007
Academic Article
GET IT
Times cited: 60 -
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
Circulation.
2007
Academic Article
GET IT
Times cited: 45 -
Respiratory effects of exposure to diesel traffic in persons with asthma.
The New England journal of medicine.
2007
Academic Article
GET IT
Times cited: 726 -
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes.
The American journal of cardiology.
2007
Review
GET IT
Times cited: 25 -
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Circulation.
2007
Academic Article
GET IT
Times cited: 42 -
Clinical decisions. Management of stable coronary disease.
2007
GET IT
Times cited: 8 -
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Journal of the American College of Cardiology.
2007
Academic Article
GET IT
Times cited: 442 -
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Journal of the American College of Cardiology.
2007
Academic Article
GET IT
Times cited: 481 -
Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting.
The American journal of cardiology.
2007
Academic Article
GET IT
Times cited: 26 -
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
Journal of interventional cardiology.
2007
Academic Article
GET IT
Times cited: 7 -
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2007
Academic Article
GET IT
Times cited: 7 -
Primary percutaneous coronary intervention in acute myocardial infarction.
The Medical clinics of North America.
2007
Review
GET IT
Times cited: 13 -
Women, acute ischemic heart disease, and antithrombotic therapy: challenges and opportunities.
Circulation.
2007
Editorial Article
GET IT
Times cited: 5 -
Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
The Journal of thoracic and cardiovascular surgery.
2007
Academic Article
GET IT
Times cited: 22 -
The enigma of drug-eluting stents: hope, hype, humility, and advancing patient care.
JAMA.
2007
Editorial Article
GET IT
Times cited: 13 -
Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
Expert review of cardiovascular therapy.
2007
Review
GET IT
Times cited: 8 -
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.
European heart journal.
2007
Academic Article
GET IT
Times cited: 56 -
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes.
European heart journal.
2007
Review
GET IT
Times cited: 236 -
Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction.
American heart journal.
2007
Academic Article
GET IT
Times cited: 51 - ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases. Journal of the American College of Cardiology. 2007 Conference Paper GET IT
-
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.
JAMA.
2007
Academic Article
GET IT
Times cited: 319 -
Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
The American journal of cardiology.
2007
Academic Article
GET IT
Times cited: 20 - ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases. Circulation. 2007 Conference Paper GET IT
-
Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative).
The American journal of cardiology.
2007
Academic Article
GET IT
Times cited: 41 -
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
The Annals of thoracic surgery.
2007
Academic Article
GET IT
Times cited: 80 -
Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions.
JAMA.
2007
Editorial Article
GET IT
Times cited: 8 -
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials.
European heart journal.
2007
Review
GET IT
Times cited: 18 -
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock.
The American journal of cardiology.
2007
Academic Article
GET IT
Times cited: 19 -
ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography).
Circulation.
2007
Conference Paper
GET IT
Times cited: 468 -
A comparison of acute coronary syndrome care at academic and nonacademic hospitals.
The American journal of medicine.
2007
Academic Article
GET IT
Times cited: 56 -
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2007
Academic Article
GET IT
Times cited: 105 -
Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics.
Health affairs (Project Hope).
2007
Academic Article
GET IT
Times cited: 28 -
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
JAMA.
2006
Academic Article
GET IT
Times cited: 814 -
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
American heart journal.
2006
Academic Article
GET IT
Times cited: 76 -
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Circulation.
2006
Academic Article
GET IT
Times cited: 166 -
Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?.
Journal of the American College of Cardiology.
2006
Editorial Article
GET IT
Times cited: 21 -
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
Archives of internal medicine.
2006
Academic Article
GET IT
Times cited: 140 -
Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts.
American heart journal.
2006
Academic Article
GET IT
Times cited: 9 -
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.
American heart journal.
2006
Academic Article
GET IT
Times cited: 125 -
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
The New England journal of medicine.
2006
Academic Article
GET IT
Times cited: 330 -
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE).
The American journal of cardiology.
2006
Academic Article
GET IT
Times cited: 43 -
Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes.
The American journal of cardiology.
2006
Academic Article
GET IT
Times cited: 37 -
Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft.
Circulation.
2006
Academic Article
GET IT
Times cited: 17 -
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
Current cardiology reports.
2006
Academic Article
GET IT
Times cited: 2 -
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
American heart journal.
2006
Academic Article
GET IT
Times cited: 14 -
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
Journal of thrombosis and thrombolysis.
2006
Academic Article
GET IT
Times cited: 14 -
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes.
American heart journal.
2006
Academic Article
GET IT
Times cited: 118 -
Statin use and sex-specific stroke outcomes in patients with vascular disease.
Stroke.
2006
Review
GET IT
Times cited: 40 -
Association between hospital process performance and outcomes among patients with acute coronary syndromes.
JAMA.
2006
Academic Article
GET IT
Times cited: 569 -
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.
Archives of internal medicine.
2006
Academic Article
GET IT
Times cited: 49 -
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
American heart journal.
2006
Academic Article
GET IT
Times cited: 198 -
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.
American heart journal.
2006
Review
GET IT
Times cited: 43 -
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
Journal of the American College of Cardiology.
2006
Academic Article
GET IT
Times cited: 286 -
Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes.
Journal of the American College of Cardiology.
2006
Academic Article
GET IT
Times cited: 65 -
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes.
European heart journal.
2006
Review
GET IT
Times cited: 32 -
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
Thrombosis research.
2006
Academic Article
GET IT
Times cited: 20 -
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
American heart journal.
2006
Academic Article
GET IT
Times cited: 20 - President's page: New York 1952 to Atlanta 2006: celebrating the cardiovascular community. Journal of the American College of Cardiology. 2005 Editorial Article GET IT
-
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
JAMA.
2005
Academic Article
GET IT
Times cited: 586 -
MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury.
Expert opinion on investigational drugs.
2005
Review
GET IT
Times cited: 22 -
Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study".
Circulation.
2005
Letter
GET IT
Times cited: 4 -
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
American heart journal.
2005
Academic Article
GET IT
Times cited: 42 -
Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes.
The American journal of cardiology.
2005
Academic Article
GET IT
Times cited: 56 -
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.
The American journal of cardiology.
2005
Academic Article
GET IT
Times cited: 549 -
Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery.
The American journal of cardiology.
2005
Academic Article
GET IT
Times cited: 95 -
Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future.
Current hematology reports.
2005
Review
GET IT
Times cited: 7 -
Renal function, concomitant medication use and outcomes following acute coronary syndromes.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2005
Academic Article
GET IT
Times cited: 67 -
Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns.
Heart (British Cardiac Society).
2005
Academic Article
GET IT
Times cited: 11 -
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
Journal of the American College of Cardiology.
2005
Academic Article
GET IT
Times cited: 40 -
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
The American journal of cardiology.
2005
Academic Article
GET IT
Times cited: 2 -
Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis?
2005
GET IT
Times cited: 1 -
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
American heart journal.
2005
Academic Article
GET IT
Times cited: 81 -
Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns.
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
2005
Academic Article
GET IT
Times cited: 34 -
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
The American journal of cardiology.
2005
Academic Article
GET IT
Times cited: 19 -
Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes.
American heart journal.
2005
Academic Article
GET IT
Times cited: 57 -
Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction.
The American journal of cardiology.
2005
Academic Article
GET IT
Times cited: 19 -
Revascularization of coronary atherosclerosis in patients with diabetes mellitus--there is more to it than meets the image intensifier.
American heart journal.
2005
Editorial Article
GET IT
Times cited: 4 -
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology.
2005
Letter
GET IT
Times cited: 29 -
Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease.
The American journal of cardiology.
2005
Academic Article
GET IT
Times cited: 32 -
Interventional cardiovascular pharmacotherapy: current issues.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2005
Review
GET IT
Times cited: 2 -
The potential of aptamers as anticoagulants.
Trends in cardiovascular medicine.
2005
Review
GET IT
Times cited: 92 -
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
European heart journal.
2004
Review
GET IT
Times cited: 16 -
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
Thrombosis and haemostasis.
2004
Letter
GET IT
Times cited: 2 -
Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Seminars in thrombosis and hemostasis.
2004
Review
GET IT
Times cited: 2 -
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Thrombosis and haemostasis.
2004
Review
GET IT
Times cited: 18 -
Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.
Journal of thrombosis and thrombolysis.
2004
Academic Article
GET IT
Times cited: 1 -
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.
JAMA.
2004
Academic Article
GET IT
Times cited: 496 -
Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative.
American heart journal.
2004
Academic Article
GET IT
Times cited: 57 -
Task force 1: The ACCF and AHA codes of conduct in human subjects research.
Journal of the American College of Cardiology.
2004
Conference Paper
GET IT
Times cited: 6 -
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.
JAMA.
2004
Academic Article
GET IT
Times cited: 898 -
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest.
2004
Guideline
GET IT
Times cited: 243 -
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest.
2004
Guideline
GET IT
Times cited: 214 -
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest.
2004
Guideline
GET IT
Times cited: 85 -
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Lancet (London, England).
2004
Academic Article
GET IT
Times cited: 488 -
Myocardial ischemia and infarction.
Journal of the American College of Cardiology.
2004
Academic Article
GET IT
Times cited: 2 -
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.
Circulation.
2004
Academic Article
GET IT
Times cited: 50 -
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
JAMA.
2004
Review
GET IT
Times cited: 317 -
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
JAMA.
2004
Academic Article
GET IT
Times cited: 710 - Antithrombotic therapy and the invasive cardiac catheterization management strategy: the intracoronary stenting with antithrombotic regimen cooling-off trial. Current cardiology reports. 2004 Comment GET IT
-
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT.
American heart journal.
2004
Academic Article
GET IT
Times cited: 37 - Moderate versus aggressive lipid lowering with statins following an acute coronary syndrome: the pravastatin or atorvastatin evaluation and infection therapy trial. Current cardiology reports. 2004 Comment GET IT
-
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology.
2004
Review
GET IT
Times cited: 53 -
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.
The American journal of cardiology.
2004
Academic Article
GET IT
Times cited: 46 -
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
The Canadian journal of cardiology.
2004
Academic Article
GET IT
Times cited: 1 -
Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction.
American heart journal.
2004
Academic Article
GET IT
Times cited: 24 -
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
The American journal of cardiology.
2004
Academic Article
GET IT
Times cited: 200 -
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.
Journal of the American College of Cardiology.
2004
Academic Article
GET IT
Times cited: 5 -
Aspirin dose and six-month outcome after an acute coronary syndrome.
Journal of the American College of Cardiology.
2004
Academic Article
GET IT
Times cited: 46 -
Economic impact of drug-eluting stents on hospital systems: a disease-state model.
American heart journal.
2004
Academic Article
GET IT
Times cited: 36 -
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study).
The American journal of cardiology.
2004
Academic Article
GET IT
Times cited: 74 -
Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology.
2004
Academic Article
GET IT
Times cited: 23 -
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.
Circulation.
2004
Academic Article
GET IT
Times cited: 33 -
Conflict of interest.
American heart journal.
2004
Conference Paper
GET IT
Times cited: 29 -
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
European heart journal.
2004
Academic Article
GET IT
Times cited: 60 -
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
Journal of thrombosis and haemostasis : JTH.
2004
Academic Article
GET IT
Times cited: 44 - Multi-bed vascular disease: past, present, and future. Journal of thrombosis and thrombolysis. 2004 Review GET IT
-
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes.
The American journal of medicine.
2004
Review
GET IT
Times cited: 3 -
Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.
American heart journal.
2004
Academic Article
GET IT
Times cited: 11 -
GP IIb/IIIa blockade in elective percutaneous coronary intervention.
Current pharmaceutical design.
2004
Review
GET IT
Times cited: 3 - Prolonged antithrombotic pretreatment increased risk for MI or death in unstable coronary syndromes. ACP journal club. 2004 Comment GET IT
-
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.
The American journal of medicine.
2003
Academic Article
GET IT
Times cited: 4 -
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
The Journal of invasive cardiology.
2003
Academic Article
GET IT
Times cited: 168 -
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.
JAMA.
2003
Academic Article
GET IT
Times cited: 179 -
Advances and continued controversy in coronary revascularization of patients with diabetes mellitus.
Current diabetes reports.
2003
Review
GET IT
Times cited: 1 -
Changing the model of care for patients with acute coronary syndromes.
American heart journal.
2003
Review
GET IT
Times cited: 57 -
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
American heart journal.
2003
Academic Article
GET IT
Times cited: 91 -
Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.
The American journal of cardiology.
2003
Review
GET IT
Times cited: 87 -
Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).
The American journal of cardiology.
2003
Academic Article
GET IT
Times cited: 20 -
Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes.
The American journal of medicine.
2003
Academic Article
GET IT
Times cited: 23 -
Cardiology patient page. Antiplatelet therapy.
Circulation.
2003
Academic Article
GET IT
Times cited: 19 -
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
The American journal of cardiology.
2003
Academic Article
GET IT
Times cited: 39 -
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Circulation.
2003
Academic Article
GET IT
Times cited: 196 -
Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.
The American journal of cardiology.
2003
Academic Article
GET IT
Times cited: 44 -
Poverty, process of care, and outcome in acute coronary syndromes.
Journal of the American College of Cardiology.
2003
Academic Article
GET IT
Times cited: 62 -
Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture.
Journal of thrombosis and thrombolysis.
2003
Academic Article
GET IT
Times cited: 45 -
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
Journal of the American College of Cardiology.
2003
Academic Article
GET IT
Times cited: 101 -
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
JAMA.
2003
Academic Article
GET IT
Times cited: 1042 -
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.
Journal of the American College of Cardiology.
2003
Academic Article
GET IT
Times cited: 99 -
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Journal of the American College of Cardiology.
2003
Academic Article
GET IT
Times cited: 80 - Clopidogrel after percutaneous coronary intervention was effective. ACP journal club. 2003 Comment GET IT
- Fluvastatin reduced major adverse cardiac outcomes after first percutaneous coronary intervention. ACP journal club. 2003 Comment GET IT
-
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.
American heart journal.
2003
Academic Article
GET IT
Times cited: 93 -
Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2003
Review
GET IT
Times cited: 24 -
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
American heart journal.
2002
Academic Article
GET IT
Times cited: 49 -
Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative.
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
2002
Academic Article
GET IT
Times cited: 198 -
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Circulation.
2002
Academic Article
GET IT
Times cited: 129 -
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.
Circulation.
2002
Academic Article
GET IT
Times cited: 429 -
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
Journal of thrombosis and thrombolysis.
2002
Academic Article
GET IT
Times cited: 9 -
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Lancet (London, England).
2002
Letter
GET IT
Times cited: 39 -
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
Circulation.
2002
Review
GET IT
Times cited: 115 -
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
European heart journal.
2002
Academic Article
GET IT
Times cited: 7 -
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
The American journal of medicine.
2002
Review
GET IT
Times cited: 45 -
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Circulation.
2002
Academic Article
GET IT
Times cited: 82 -
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?.
Circulation.
2002
Academic Article
GET IT
Times cited: 174 -
Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: has the time come for 'drive-through' angiography?.
European heart journal.
2002
Editorial Article
GET IT
Times cited: 1 -
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
American heart journal.
2002
Academic Article
GET IT
Times cited: 66 -
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Circulation.
2002
Academic Article
GET IT
Times cited: 57 -
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Lancet (London, England).
2002
Review
GET IT
Times cited: 918 -
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
Cardiology.
2002
Academic Article
GET IT
Times cited: 7 - Primary percutaneous coronary intervention was more effective than thrombolytic therapy for acute MI. ACP journal club. 2002 Comment GET IT
-
The bent stent.
2002
GET IT
Times cited: 1 -
American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee).
Journal of the American College of Cardiology.
2001
Academic Article
GET IT
Times cited: 605 - Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current controlled trials in cardiovascular medicine. 2001 Academic Article GET IT
- Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current controlled trials in cardiovascular medicine. 2001 Academic Article GET IT
-
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up.
Journal of the American College of Cardiology.
2001
Academic Article
GET IT
Times cited: 104 -
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network.
Journal of the American College of Cardiology.
2001
Academic Article
GET IT
Times cited: 140 -
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
Journal of the American College of Cardiology.
2001
Academic Article
GET IT
Times cited: 30 -
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
Chest.
2001
Review
GET IT
Times cited: 104 -
Intravenous thrombolysis in acute myocardial infarction.
Chest.
2001
Review
GET IT
Times cited: 64 -
"Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship.
The Journal of invasive cardiology.
2000
Comment
GET IT
Times cited: 1 -
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
Circulation.
2000
Academic Article
GET IT
Times cited: 177 - Clinical trials report. Current cardiology reports. 2000 Academic Article GET IT
-
Risk stratification and therapeutic decision making in acute coronary syndromes.
JAMA.
2000
Comment
GET IT
Times cited: 151 -
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
Circulation.
2000
Academic Article
GET IT
Times cited: 34 -
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Circulation.
2000
Academic Article
GET IT
Times cited: 841 -
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
American heart journal.
2000
Academic Article
GET IT
Times cited: 72 -
Age and outcome after acute coronary syndromes without persistent ST-segment elevation.
American heart journal.
2000
Academic Article
GET IT
Times cited: 71 -
What have we learned from the recent large trials in acute coronary syndromes without ST-segment elevation?.
European heart journal.
2000
Editorial Article
GET IT
Times cited: 3 -
Cardiac enzyme elevations after percutaneous coronary intervention: myonecrosis, the coronary microcirculation and mortality.
Journal of the American College of Cardiology.
2000
Editorial Article
GET IT
Times cited: 12 -
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
American heart journal.
2000
Academic Article
GET IT
Times cited: 17 -
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
European heart journal.
2000
Academic Article
GET IT
Times cited: 67 -
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
Circulation.
2000
Academic Article
GET IT
Times cited: 102 -
Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study).
The Canadian journal of cardiology.
1999
Academic Article
GET IT
Times cited: 8 -
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
American heart journal.
1999
Review
GET IT
Times cited: 24 -
Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States.
Clinical cardiology.
1999
Review
GET IT
Times cited: 15 - Recent clinical trials in acute coronary syndromes without persistent ST elevation. Current opinion in cardiology. 1999 Review GET IT
- Recent trials of antithrombotics in the management of patients with acute coronary syndromes. Current cardiology reports. 1999 Review GET IT
-
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.
Journal of thrombosis and thrombolysis.
1999
Review
GET IT
Times cited: 1 -
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Circulation.
1999
Academic Article
GET IT
Times cited: 72 -
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators.
American heart journal.
1999
Academic Article
GET IT
Times cited: 10 -
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
Circulation.
1998
Review
GET IT
Times cited: 354 -
Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Drugs.
1998
Review
GET IT
Times cited: 20 -
Improved outlook for patients with acute myocardial infarction: an interim progress report.
European heart journal.
1998
Editorial Article
GET IT
Times cited: 1 -
Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions.
Journal of the American College of Cardiology.
1998
Academic Article
GET IT
Times cited: 30 -
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
Journal of the American College of Cardiology.
1998
Academic Article
GET IT
Times cited: 151 - Platelet Inhibition in Cardiovascular Disease Management: Aspirin and Beyond. Journal of thrombosis and thrombolysis. 1998 Academic Article GET IT
-
Antiplatelet and antithrombin therapies in the acute coronary syndromes.
Current opinion in cardiology.
1997
Review
GET IT
Times cited: 12 -
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Journal of the American College of Cardiology.
1997
Academic Article
GET IT
Times cited: 210 -
Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
1997
GET IT
Times cited: 203 -
Adjunctive Antiplatelet Therapy in Acute Myocardial Infarction: The Road to Improved Infarct-Related Artery Patency.
Journal of thrombosis and thrombolysis.
1997
Academic Article
GET IT
Times cited: 2 -
Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective.
Journal of thrombosis and thrombolysis.
1997
Academic Article
GET IT
Times cited: 3 -
Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Circulation.
1996
Academic Article
GET IT
Times cited: 37 -
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Circulation.
1996
Academic Article
GET IT
Times cited: 120 -
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
The American journal of cardiology.
1995
Academic Article
GET IT
Times cited: 188 -
Percutaneous revascularization of chronic coronary occlusions: an overview.
Journal of the American College of Cardiology.
1995
Review
GET IT
Times cited: 225 -
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).
Journal of the American College of Cardiology.
1995
Academic Article
GET IT
Times cited: 148 -
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
Circulation.
1995
Academic Article
GET IT
Times cited: 269 -
Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.
Circulation.
1995
Academic Article
GET IT
Times cited: 214 -
Antithrombotic Therapy during Percutaneous Coronary Intervention.
Journal of thrombosis and thrombolysis.
1995
Academic Article
GET IT
Times cited: 3 -
Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study.
Journal of thrombosis and thrombolysis.
1995
Academic Article
GET IT
Times cited: 22 -
Tuberculin booster reactions and conversions.
Annals of internal medicine.
1994
Letter
GET IT
Times cited: 1 - The role of angioplasty after failed thrombolysis for acute myocardial infarction. Coronary artery disease. 1994 Review GET IT
-
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Circulation.
1994
Academic Article
GET IT
Times cited: 171 -
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Journal of the American College of Cardiology.
1994
Academic Article
GET IT
Times cited: 57 -
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part II.
American heart journal.
1991
Review
GET IT
Times cited: 3 -
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part I.
American heart journal.
1991
Guideline
GET IT
Times cited: 8